Daedeok gu, South Korea
Daedeok gu, South Korea

Time filter

Source Type

The present invention relates to a novel siRNA, and a high-efficiency double-stranded oligo RNA structure containing the same, and a nanoparticle containing the high-efficiency double-stranded oligo RNA structure. The double-stranded oligo RNA structure has a structure in which a hydrophilic material and a hydrophobic material are conjugated to both ends of a double-stranded oligo RNA (siRNA) via a simple covalent bond or linker-mediated covalent bond in order to be efficiently delivered into cells, and may be converted into a nanoparticle form in an aqueous solution by hydrophobic interactions of double-stranded oligo RNA structures. It is preferable that the siRNA contained in the double-stranded oligo RNA structure is an siRNA specific for fibrosis or respiratory disease-related gene, particularly, amphiregulin or stratifin. In addition, the present invention relates to a pharmaceutical composition for preventing or treating fibrosis or respiratory diseases, containing an siRNA, a high-efficiency double-stranded oligo RNA structure containing the siRNA, or a nanoparticle containing the high-efficiency double-stranded oligo RNA structure, as an active ingredient. In addition, the present invention relates to a method of preventing or treating fibrosis or respiratory diseases, including administering the pharmaceutical composition for preventing or treating fibrosis or respiratory diseases to a subject in need thereof.


Provided is a ceramic paste composition including carbon nanotubes or a carbon nanotube-metal composite and a silicone adhesive, wherein the silicone adhesive includes 45 to 65 wt% of silicon dioxide, and 0.1 to 10 wt% of a silanol group, and has a weight ratio of a methyl group: a phenyl group of 1: 0.3 to 2.5. The ceramic paste composition according to the present invention is characterized by having low sheet resistance, through which an excellent heat generating property, and shielding, absorbing and conducting properties may be implemented. Further, though the ceramic paste composition has a very high heat generating temperature of 400 C, as compared with general paste based on carbon nanotubes, the physical properties thereof may be maintained stably, thereby implementing the inherent properties of ceramic paste. In addition, the ceramic paste may be easily formed into a planar conductive film by a simple process, and thus, widely used in various fields including heat generating products such as those for keeping warmth or heating, and products for electromagnetic wave shielding and absorption, electrodes, electronic circuits, antennas, and the like.


The present invention relates to a method for preparing highly active silica magnetic nanoparticles, highly active silica magnetic nanoparticles prepared by the method, and a method of isolating nucleic acid using the highly active silica magnetic nanoparticles. The highly active silica magnetic nanoparticles prepared according to the present invention contain magnetic nanoparticles completely coated with silica, can be used as a reagent for isolating biomaterials, particularly, nucleic acids, and can isolate and purify nucleic acid in a high yield.


The present invention relates to a method for preparing a nucleic acid with high sensitivity, wherein a nucleic acid polymerase is used to add a terminator to the nucleic acid to be used for analysis prior to a nucleic acid polymerization reaction such as a PCR reaction, a real time quantitative PCR reaction, or the like, for detecting a trace of nucleic acid, such that a non-specific priming occurring competitively with an amplification reaction of a target nucleic acid may be basically eliminated, thereby precisely detecting only the trace of target nucleic acid and precisely measuring a concentration of the target nucleic acid.


The present invention relates to a dengue virus-specific siRNA, a high-efficiency double helix oligo-RNA structure comprising the siRNA, and a composition for suppressing the proliferation of dengue virus comprising the RNA structure. The double helix oligo-RNA structure has a structure in which a hydrophilic material and a hydrophobic material are grafted on both ends of a double helix RNA (siRNA) via a simple covalent bond or a linker-mediated covalent bond so that the double helix oligo-RNA structure is efficiently delivered into cells, and can be transformed into a nanoparticle type by a hydrophobic interaction of the double helix RNA structures in an aqueous solution. The siRNA included in the double helix oligo-RNA structure specifically acts on the serotype of all dengue viruses. In addition, the present invention relates to a method for preparing the double helix oligo-RNA structure, and a pharmaceutical composition containing the double helix oligo-RNA structure for preventing or treating a dengue virus infection.


The present invention relates to a magnetic particle separating device, and a method of separating and purifying nucleic acid or protein using the same. The device comprises: induction magnets (100); an induction magnet fixing part (200) having induction magnet fixing holes (210) for fixing the induction magnets (100); and a body (300) in which entry holes (310) are formed into which tubes (T) are inserted. Thus, the application and removal of a magnetic field to and from the body is made very convenient, so that the device can be very advantageously used in the separation and purification of nucleic acid or protein.


Patent
Bioneer Corporation | Date: 2015-08-05

The present invention relates to a reverse transcriptase having improved thermostability, more precisely a mutant reverse transcriptase with improved thermostability by substitution of one or more amino acids selected from the group consisting of the 63rd glutamine (Q63), the 264th lysine (K264), the 295th lysine (K295), the 306th threonine (T306), the 346th glutamic acid (E346), the 408th proline (P408), the 438th histidine (H438), and the 454th asparagin (N454) of the amino acid sequence of M-MLV originated reverse transcriptase represented by SEQ. ID. NO: 1 with other amino acids. The mutant reverse transcriptase of the present invention demonstrates excellent thermostability, compared with the wild type reverse transcriptase. Therefore, it is advantageous to obtain the target cDNA with stable reverse transcription activity even in the presence of RNA that can form the stable secondary structure at a high temperature which is a structural barrier for reverse transcription.


Patent
Bioneer Corporation | Date: 2016-09-28

The present invention relates to a microchamber plate, and more particularly, to a microchamber plate having microchamber holes formed using a flowable film. Thus, samples can be injected into the microchamber holes in a smoother manner compared to when samples are injected using a vacuum and/or centrifugal force. In addition, bubbles and excess samples in the microchamber holes can be efficiently discharged, making it possible to perform reaction and analysis in a more accurate and efficient manner.


The present invention relates to respiratory diseases, especially to gene specific siRNA related to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), and a highly efficient double-helical oligo RNA structure containing the same, wherein the double-helical oligo RNA structure has a structure in which hydrophilic and hydrophobic materials are bonded at the both ends of the double-helical RNA (siRNA) using a simple covalent bond or a linker-mediated covalent bond to be effectively transferred into a cell, and is converted into nanoparticles by the hydrophobic interaction of the double-helical oligo RNA structure in a solution. It is desirable that the siRNA contained in the double-helical oligo RNA structure is a siRNA specific to a CTGF, Cyr61, or Plekho1, which are genes related to respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD. In addition, the present invention relates to a method for producing the double-helical oligo RNA structure and a pharmaceutical composition containing the double-helical oligo RNA structure for preventing or treating respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD.


The present invention relates to an oligonucleotide structure and a method for preparing the same and, more particularly, to an oligonucleotide structure in which a polymer compound is linked to an oligonucleotide via a covalent bond to improve in vivo stability of the oligonucleotide and cellular delivery efficiency of the oligonucleotide; and to a method for preparing the same. The oligonucleotide structure is improved into a homogenous material, thereby solving the problem in material verification due to polydispersion characteristics occurring when a hydrophilic material linked to the oligonucleotide is a synthetic polymer; the nucleotide structure is easy to synthesize compared with the existing process; and the size of a double helix oilgo-RNA structure can be accurately adjusted through the control of the number of repetitions of a hydrophilic material block, and thus, the gene expression regulation function of the oligonucleotide does not deteriorate through the synthesis of the optimized oligonucleotide structure, and the oligonucleotide can be delivered into cells at even a relatively low-concentration dosage. Therefore, the oligonucleotide structure of the present invention can be useful as a novel type oligonucleotide delivery system as well as a tool for treating cancers, infectious diseases, and the like.

Loading Bioneer Corporation collaborators
Loading Bioneer Corporation collaborators